Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of “Hold” by Brokerages

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have earned a consensus rating of “Hold” from the five brokerages that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $11.9750.

Several equities research analysts have commented on the stock. Guggenheim set a $11.00 price target on shares of Valneva in a research report on Thursday, April 16th. The Goldman Sachs Group downgraded shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a research note on Wednesday, April 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st.

Institutional Trading of Valneva

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marex Group plc bought a new stake in Valneva during the 2nd quarter worth $64,000. XTX Topco Ltd acquired a new stake in Valneva during the 4th quarter worth about $94,000. JPMorgan Chase & Co. bought a new position in shares of Valneva in the 3rd quarter worth about $124,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Valneva in the 4th quarter worth about $44,000. Finally, VSM Wealth Advisory LLC lifted its stake in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the period. Institutional investors own 11.39% of the company’s stock.

Valneva Stock Performance

Shares of VALN stock opened at $5.05 on Monday. The company has a market capitalization of $479.17 million, a P/E ratio of -2.70 and a beta of 1.77. Valneva has a 52 week low of $5.04 and a 52 week high of $12.25. The company’s 50 day moving average price is $5.55 and its two-hundred day moving average price is $7.64. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14.

Valneva (NASDAQ:VALN) last announced its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The company had revenue of $35.77 million during the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. On average, analysts expect that Valneva will post -1 earnings per share for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.